

## Orthocell Records Seventh Consecutive Quarter of Record Revenue at \$3.2m

- Record quarterly revenue of \$3.2 million was achieved for the quarter ended 31 December 2025, underpinned by continued growth in sales of the Remplir™ nerve repair product in existing markets and initial contributions from the United States. This included approximately \$90k in Remplir U.S. sales in December, in line with expectations.
- December quarter revenue represents a 7.0% increase over the previous quarterly record of \$3.0 million achieved in the September 2025 quarter and a 45.2% increase on the prior corresponding period.
- This result is the seventh consecutive quarter of record revenue, with a Compound Quarterly Growth Rate ("CQGR") of 10.4% since Q3 FY24.
- Early U.S. results indicate the hybrid market entry strategy, combining specialist distributors with internal field leadership, is successful and delivering positive momentum.
- Highlights of the US commercialisation of Remplir include:
  - A distributor network that now covers 25+ States and 40% of the US population;
  - Submission of 61 applications to hospital Value Analysis Committees (VAC) in progress, of which 23 have been approved, ahead of schedule; and
  - Completion of 11 major medical education meetings in key U.S. states introducing surgeons to Remplir's advanced nerve repair capabilities and clinical evidence supporting improved surgical workflow and patient care.
- The second Canadian distributor was recently appointed, and initial sales from this region are targeted for the March quarter with market adoption expected to grow steadily in 2026.
- Orthocell maintains robust cash reserves of \$49.4 million<sup>1</sup> and is well positioned to support continued commercial expansion. The Company also expects to receive an R&D tax incentive refund of approximately \$3.0 million in the March quarter FY26.
- Full Quarterly Activity Report and Appendix 4C to be released by Friday, 23 January 2026.

**Perth, Australia; 6 January 2026:** Regenerative medicine company Orthocell Limited (ASX:OCC, "Orthocell" or the "Company") is pleased to announce a record quarterly revenue result of \$3.2 million for the quarter ended 31 December 2025.

<sup>1</sup> As at 31 December 2025, the total cash reserves were \$49.4 m, comprising \$7.4 m in cash and cash equivalents and \$42.0m in term deposits with maturities of 3 to 12 months.

The December quarter's revenue represents a 7.0% increase over the previous quarter and a 45.2% increase on the prior corresponding period, marking the seventh consecutive quarter of record revenue. The Company has achieved a CQGR of 10.4% since Q3 FY24 (Figure 1).

Importantly, the record revenue performance was primarily driven by increased market penetration in existing markets, particularly Australia, as well as initial financial contributions from early Remplir surgical cases in the United States. The anticipated growth in Remplir adoption by U.S. surgeons represents the potential for a strong increase in revenue going forward, with momentum expected to build through 2026.

Growth in Remplir sales is expected to be further supported by entry into the Canadian market. Following the recent appointment of a second Canadian distributor, initial sales are targeted for the March quarter FY26, with market adoption anticipated to grow steadily throughout 2026.




Figure1: Quarterly Revenue

**Orthocell CEO and MD, Paul Anderson, said:**

“The seventh consecutive record revenue result for the December quarter is particularly pleasing, driven by strong performance in existing markets and early Remplir unit sales in the U.S. Early U.S. results show our hybrid market entry strategy, combining specialist distributors with internal field leadership, is successful and delivering positive momentum. With the U.S. momentum building and Canada coming online, we see significant upside as we replicate the successful Australia and Singapore approach on a larger scale in the U.S.”

With \$49.4 million<sup>1</sup> in cash reserves, no debt and an R&D tax incentive refund of approximately \$3.0 million expected to be received in the March quarter FY26, Orthocell is well-positioned to drive rapid product adoption and deliver a step change in revenue in FY26. Remplir rollout in the US\$1.6 billion<sup>2</sup> US market continues to gain momentum, with in-country representatives working with specialist distributors to secure

<sup>2</sup> Nerve repair market sizes estimated using referenced papers from both US and OUS databases and studies.

hospital approvals, on-board surgeons, and establish active accounts. Early surgical cases are building, demonstrating the effectiveness of Orthocell's hybrid market entry strategy — combining distributor networks, internal field leadership, and targeted medical education programs.

Orthocell has completed 11 major U.S. medical education meetings, with a further 10 scheduled in the coming months, supporting clinician training, strengthening adoption, and fostering centers of excellence in nerve repair. These initiatives lay the foundation for sustained growth and replicate the successful market entry approach previously implemented in Australia and Singapore.

Orthocell expects to release its full Quarterly Activity Report and Appendix 4C by Friday, 23 January 2026.

**Release authorised by:**

**Paul Anderson**

**Orthocell Ltd CEO and MD**

**For more information, please contact:**

**General enquiries**

**Paul Anderson**

Orthocell Limited  
CEO and MD

P: +61 8 9360 2888

E: [paul.anderson@orthocell.com](mailto:paul.anderson@orthocell.com)

**Media enquiries**

**Haley Chartres**

**H<sup>^</sup>CK Director**

P: +61 423 139 163

E: [haley@hck.digital](mailto:haley@hck.digital)

**Investor enquiries**

**Shaun Duffy**

**VECTOR Advisors**

P: +61 404 094 384

E: [sduffy@vectoradvisors.au](mailto:sduffy@vectoradvisors.au)

**About Orthocell Limited**

**ACN 118 897 135**

Registered Office – Building 191 Murdoch University, 90 South Street, Murdoch WA 6150 Australia

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Orthocell's portfolio of products include a platform of collagen medical devices which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications. Striate+™ was the first product approved for dental GBR applications, is cleared for use in the US, Australia, New Zealand, Singapore, UK, Europe, Canada and Brazil and is distributed globally by BioHorizons Implant Systems Inc. Remplir™, for peripheral nerve reconstruction, recently gained clearance for use in the US. The Company has appointed 14 US distributors and recorded initial sales. The Company's flagship nerve repair product is also approved in Australia, New Zealand and Singapore where it is distributed by Device Technologies Group. Other Remplir approvals include Thailand and Canada. SmrtGraft™, for tendon repair, is available in Australia under Special Access Scheme or participation in a clinical trial. The Company's other major products are autologous cell therapies which aim to regenerate damaged tendon and cartilage tissue. Orthocell is accelerating the development of its tendon cell therapy in the US with technology transfer and FDA engagement to confirm the path to the US market and prepare for partnering discussions.

**For more information on Orthocell, please visit [www.orthocell.com](http://www.orthocell.com) or follow us on Twitter**

**@OrthocellLtd and LinkedIn [www.linkedin.com/company/orthocell-ltd](http://www.linkedin.com/company/orthocell-ltd)**

## Forward Looking Statement

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.